Annovis Bio Inc. (NYSE: ANVS) has promoted Cheng Fang, Ph.D., to the position of chief scientific officer, the company announced Tuesday. Fang, who joined Annovis in 2021 and most recently served as senior vice president of research and development, will now oversee scientific strategy and research operations across the company’s Alzheimer’s disease and Parkinson’s disease programs. His responsibilities include translational science, clinical development, biomarker strategy and regulatory interactions.
The promotion comes at a critical juncture for Annovis as it advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer’s disease study and a subsequent New Drug Application submission. The company stated that Fang has played a key role in advancing its clinical development efforts and will lead scientific strategy through upcoming clinical and regulatory milestones.
Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins—including APP, amyloid beta, tau, alpha-synuclein, and TDP-43—through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The drug is being developed for both Alzheimer’s disease and Parkinson’s disease, two of the most prevalent neurodegenerative conditions affecting millions worldwide.
For investors, the appointment signals that Annovis is positioning its leadership team for the critical late-stage development phase. The company is a Phase 3 clinical-stage biotechnology firm headquartered in Malvern, Pennsylvania. The success of buntanetap in the upcoming Phase 3 trial could have significant implications for the neurodegenerative disease treatment landscape, where disease-modifying therapies remain largely elusive. If approved, buntanetap could offer a novel approach by targeting multiple neurotoxic proteins simultaneously.
For more details on the announcement, visit the full press release at https://ibn.fm/c9jdt. Additional information about Annovis Bio is available on its website at https://www.annovisbio.com.
